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Understanding signal transduction mechanisms that drive diﬀerentiation of adult or embryonic stem cells (ESCs) is imperative
if they are to be used to cure disease. While the list of signaling pathways regulating stem cell diﬀerentiation is growing,
it is far from complete. Indentifying regulatory mechanisms and timecourse commitment to cell lineages is needed for
generating pure populations terminally diﬀerentiated cell types, and in ESCs, suppression of teratoma formation. To this end,
we investigated speciﬁc signaling mechanisms involved in cardiomyogenesis, followed by manipulation of these pathways to
enhance diﬀerentiation of ESCs into cardiomyocytes. Subjecting nascent ESC-derived cardiomyocytes to a proteomics assay, we
found that cardiomyogenesis is inﬂuenced by up- and down-regulation of a number of kinases, one of which, cGMP-dependent
protein kinase (PKG), is markedly down-regulated during diﬀerentiation. Delving further, we found that manipulating the PKG
pathway using PKG-speciﬁc inhibitors produced signiﬁcantly more cardiomyocytes from ESCs when compared to ESCs left to
diﬀerentiate without inhibitors. In addition, we found combinatorial eﬀects when culturing ESCs in inhibitors to PKG and PKC
isotypes. Consequently, we have generated a novel hypothesis: Down-regulation of PKG and speciﬁc PKC pathways are necessary
for cardiomyogenesis, and when manipulated, these pathways produce signiﬁcantly more cardiomyocytes than untreated ESCs.
1.Introduction
To achieve the goals of stem cell therapies, the varying
mechanisms that regulate the transition of adult or embry-
onic stem cells from undiﬀerentiated to their diﬀerentiated
states must be understood. This concept is important for
producing bona ﬁde terminally diﬀerentiated cell types from
ES cells preventing teratoma formation. A prime candidate
for stem cell therapy is to repair infarcted areas as a result of
heart disease. The challenge has been to ﬁnd repair mecha-
nisms that prevent cell death inherent in cardiac remodeling
and introduce nascent cardiomyocytes that restore heart
function. A possible answer to this challenge is adult or
ES cell-derived cardiomyoplasty [1–4]. However, without
detailed comprehension of mechanisms that regulate ES cell
diﬀerentiation, quality control issues abound once they are
considered for clinical use.
As in the embryo, ES cell diﬀerentiation is thought to
be an inductive process, in which development of each
germ layer inﬂuences the other germ layers. Once we
understand how a stem cell commits to a certain fate, forever
surrendering its pluripotency, we can use this knowledge to
enhance fate-directed ES-like cell diﬀerentiation.
With this concept in mind, we previously demonstrated
the functional importance of the JAK/STAT3 [5]a n dP K C
pathways in ES cells as they diﬀerentiate into beating
cardiomyocytes [6]. Here, we not only reveal the functional
importance of PKG, but also we show how this pathway can2 Stem Cells International
be manipulated to induce ES cells to form signiﬁcantly more
cardiomyocytes than in controls.
PKG is a well-studied serine/threonine protein kinase
in many systems [7–9]. In vascular smooth muscle, PKG1
has been shown to activate myosin light-chain (MLC)
phosphatasebyphosphorylatingitsmyosin-bindingsubunit,
consequently inhibiting MLC phosphorylation and contrac-
tion [10]. Recent evidence has shown that PKG activation
can interfere with cardiac function by phosphorylating and
inhibiting the cardiac L-type CA2+ channel current (ICa,L)
and, along with PKA, reducing the voltage-dependent fast
Na+ current in mammalian ventricular myocytes [11].
Based on evidence linking PKG1 with attenuated muscle
contraction, combined with a kinase expression screen
(Figure 1) implicating the loss of PKG1 in cardiomyocytes,
we hypothesized that PKG1 must be downregulated so that
ES cells can complete diﬀerentiation into beating cardiomy-
ocytes. Moreover, based on our previous work, we hypothe-
sized that manipulating the PKG and PKC pathways would
produce signiﬁcantly more cardiomyocytes than untreated
ES cells. To test our hypotheses, we exposed ES cells to
speciﬁc PKG inhibitors and analyzed ES cell diﬀerentiation.
We found that inhibiting PKG1 in ES cells during diﬀeren-
tiation promoted cardiomyogenesis compared to controls.
Furthermore combining antagonists to PKC isotypes [6]a n d
PKG1 clearly increased production of cardiomyocytes.
2.MaterialsandMethods
2.1. Cells. Pluripotent CCE-type mouse ES cells [12]w e r e
maintainedasdescribedin[5,6,13]andinducedtodiﬀeren-
tiated following established protocols [5, 6, 13]. After 7 days
in suspension, EBs were manually removed from suspension
dishes and placed into each well of a 24-well plate in LIF-
deﬁcient medium. Rhythmic beating of EBs was monitored
during days 11 through 18 using phase microscopy. EBs were
plated, with the following experimental model: control EBs,
control EBs with DMSO, EBs with PKG1 inhibitor, as well as
E B sw i t hP K Ga n de i t h e rP K C β or PKCζ inhibitors.
2.2. Reagents. The PKG1α cell-permeable inhibitor DT-3
was purchased from Calbiochem (San Diego, CA) and was
dissolved in DMSO at 100X. DT-3 is a molecular inhibitor
rather than a pharmacological agent, and is part of the
regulatory subunit that speciﬁcally binds to and inhibits only
PKG1α. The working concentration of DT-3 was 50μM.
Myr-PKC pseudosubstrates were purchased from Biomol
(Plymouth Meeting, PA). Each inhibitor was dissolved in
DMSO at 100X immediately prior to use. Unused inhibitors
were aliquoted and stored at −80
◦C. PKC inhibitors are
amino acid sequences that bind to their respective RACKs
(receptor for activated protein kinase C) [6, 14, 15].
2.3. RT-PCR, qRT-PCR, Western Blot Analyses, Confocal
Microscopy, and Video Microscopy. Analyses were performed
as described in [5, 6, 13]. For qRT-PCR, all RNA
samples were prepared by extraction with the mirVana
miRNA isolation kit (Ambion, Austin, TX). Samples were
treated with DNAseI to digest and contaminate genomic
DNA and diluted to 10ng/μL. All primers were designed
with the aid of using the Promega Biomath website
http://www.promega.com/biomath/calc11.htm.c D N Aw a s
made using the RT2 First Strand Kit (C-03) and the RT
2
SYBR Green qPCR Master Mixes (PA-012) from SA Bio-
sciences (Frederick, MD). No-RT controls were performed
for all qRT-PCR reactions. Individual samples were run
in triplicate, and each experiment was repeated at least 3
times. All samples were run on the Applied Biosystems ABI
Prism 7500 system using SDS 2.1 software according to the
manufacturer’s instructions. Samples were analyzed using
thedownloadableformsavailableontheSABiosciencesweb-
sitehttp://www.sabiosciences.com/pcrarraydataanalysis.php.
GAPDH was used as the endogenous RNA control, normal-
izing each sample to its expression. All samples were run on
the Applied Biosystems ABI Prism 7500 system using SDS
2.1 software. Relative gene expression was calculated using
the 2
−ΔΔC
T method.
2.4. FACS Analysis. Analysis of ﬂow cytometry data was
identical to that in [16]. Members of the Georgetown
University Flow Cytometry Core Facility acquired and ana-
lyzed all ﬂow cytometry data. Brieﬂy, EBs were trypsinized,
ﬁxed in 4% formaldehyde, and permeabilized with 0.1%
Triton-X-100 in blocking buﬀer. Primary antibodies for
cardiac troponin were from Santa Cruz Inc. and secondary
antibodies conjugatedtoAlexaFluor488ﬂuorochromefrom
Molecular Probes (Eugene, Oregon). Primary antibodies
were added to samples for 1 hour, followed by 5 washes in
blocking buﬀer. Samples were then subjected to secondary
antibody for 1 hour followed by 5 washes in PBS. The x axis
is the ﬂuorescence level of cardiac troponin. The y axis is the
cell count. M1 marks cardiac positive cells.
2.5. Statistics. A l le x p e r i m e n t a lg r o u p si nt h i ss t u d yw e r e
replicated a minimum of 3 times. For display of data, each
point on a graph represents a mean ± standard error of the
mean (SEM; represented by error bars) for an experimental
group or observation. To determine statistical diﬀerences
between experimental groups or observation points, we
applied the Anova statistical software package provided by
MicrosoftExcel(modiﬁedt-test).Graphsandtablesshowing
percentages were analyzed in two ways: by pooling all data
together for a given treatment group or by obtaining a
percentage for each experiment and producing an SEM for
all experiments.
3. Results
3.1. PKG1 Protein and mRNA Levels Are Reduced in Beating
Areas. The raw data from the kinase expression screen
indicated a dramatic decrease of PKG1 in beating areas when
compared to nonbeating control areas (Figures 1(a)–1(c)).
Western blot analyses by two independent laboratories veri-
ﬁed PKG1 downregulation in cardiomyocytes (Figure 1(d)).
After normalizing intensity of protein levels to tubulin,
nonbeating areas were determined to have 1.7X (69%) moreStem Cells International 3
0
500
1000
1500
2000
2500
3000
3500
4000
4500
5000
70
60
50
40
30
20
10
0
(g)
Anti-trop/C
Anti-trop/C
DAPI
(f)
Anti-PKG1
Anti-PKG1
Nonbeating area
Beating area
(e)
C
o
u
n
t
s
(
m
i
n
u
t
e
)
Tubulin
PKG1
PKG1
Nonbeat
Nonbeat
Beat
Nonbeat Beat
Beat
Nonbeat Beat
Kinexus raw data
C
o
n t
r
o l
( % )
(d)
1.7 : 1
(c)
(b)
(a)
Figure 1: Graphs show raw and normalized data taken directly from the Kinexus protein kinase screen. (a) Kinexus Inc.
(http://www.kinexus.ca/) uses a highly sensitive imaging system with a 16-bit camera (Bio-Rad Fluor-S Max Multi-Imager) in combination
with quantitation software (Bio-Rad Quantity One) to quantify and analyze the chemiluminescent samples. The resulting trace quantity
for each band scanned at the maximum scan time is termed the raw data. As the relationship between scan time and band intensity is
linear over the quantiﬁable range of the signal intensity, the raw data from the scans are normalized to 60 seconds (counts per minute—
C.P.M.) for uniformity. (b) After normalization, data are converted to percentages by subtracting the control (Nonbeating) normalized
C.P.M. from the experimental (Beating) normalized C.P.M., followed by dividing the diﬀerence by the control (Nonbeating) normalized
C.P.M. and multiplying by 100. (c) The actual PKG1 bands from the Kinexus report show a stronger signal in beating areas when compared
to nonbeating areas. The red lines in (c) are generated and used by the computer to ﬁnd the correct bands. (d) Followup Western blots
conﬁrmed the Kinexus data. A ratio of PKG1 protein levels was calculated by normalizing to tubulin showing that there is 1.7X (69%) more
PKG1 in nonbeating areas versus beating areas. (e)–(g) Confocal microscopy of EBs showed higher levels of PKG1 in nonbeating areas,
represented by anticardiac troponin (e)–(f), when compared to nonbeating areas. Arrows point to PKG1 within cells negative for cardiac
troponin. Scale bar in G =100micrometer.4 Stem Cells International
Table 1: Signiﬁcance comparing treated groups to controls (for data points in Figure 3(a)) % of EBs beating.
DT-3 compared to controls
Day 12: P<. 02 Day 13: P<. 002 Day 14: P<. 008 Day 15: P<. 005 Day 16: P<. 002 Day 17: P<. 002
DT-3 + PKCζ inhibitor compared to controls
Day 12: P<. 04 Day 13: P<. 0005 Day 14: P<. 001 Day 15: P<. 0001 Day 16: P<. 001 Day 17: P<. 05
DT-3 + PKCβ inhibitor compared to controls
Day 12: P<. 001 Day 13: P<. 003 Day 14: P<. 0008 Day 15: P<. 001 Day 16: P<. 001 Day 17: P<. 003
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Figure 2: Gene expression was measured by semiquantitative RT-PCR using PKG1-speciﬁc primers. (a) Beating and nonbeating areas
of similar sizes were dissected apart as described in [4, 10], followed by RNA isolation and quantiﬁcation. Control GAPDH RT-PCR
ampliﬁcationrevealedthat35cycleswereinthelinearrangeandnucleotidesinthePCRreactionwerenotexhausted.(b)Afternormalization
to GAPDH levels, PKG1 mRNA levels were lower by approximately one-half in beating areas when compared to nonbeating areas (pixel
intensity = 70 ± 11.0 to 139 ± 19.1, resp.). A representative ratio of PKG mRNA signal revealed 1.98X more in nonbeating areas when
compared to beating areas (inset in (b)). (c) Inhibiting PKG1 resulted in dramatic and signiﬁcant (P<. 005) increase in the size of beating
areas within EBs; however, the total size of EBs was not changed by PKG inhibition (d).Stem Cells International 5
PKG1 protein than beating areas. Confocal microscopy cor-
roborated the proteomics screen (Figures 1(e)–1(g)). Newly
diﬀerentiated, beating cardiomyocytes identiﬁed by cardiac
troponin T-(Tnnt2-) positive staining (Figure 1(f)) showed
lower levels of PKG1 in beating areas when compared to
Tnnt2-negative, nonbeating areas (Figures 1(e)–1(g)). Semi-
quantitative RT-PCR revealed PKG1 mRNA levels lower by
approximately one-half in beating areas when compared to
nonbeating areas conﬁrming Western blot analyses (Figures
2(a) and 2(b)).
3.2. PKG1 Inhibition Aﬀects Cardiomyocyte Diﬀerentiation.
We then tested whether inhibiting PKG could aﬀect ES
cell diﬀerentiation into cardiomyocytes. We found that 2-3
days after treatment, beating areas in DT-3-treated EBs were
markedly larger than untreated controls (Figure 2(c)). The
same EBs examined in Figure 2(c) were measured for total
EB area (Figure 2(d)), showing that control EBs and DT-
3-treated EBs were the same size, thus providing evidence
that inhibiting PKG can generate more cardiomyocytes than
untreated controls. It is important to note the timing of
when PKG and PKC inhibitors are added. We always added
inhibitors on day 3 after plating EBs into 24-well dishes.
Adding inhibitors prior to this (e.g., when EBs were in
suspension dishes), after day 3, or after beating had already
begundid notresultinsigniﬁcantlymorebeating areaswhen
compared to controls. In fact, adding inhibitors prior to
plating prevented EBs from growing as large as untreated
EBs. We do not know the reason for this ﬁnding, but we
speculate that, while in suspension, ES cells need active
PKG and PKC for proliferation. Beating areas were measured
using a reticule in the eyepiece of a dissecting microscope or
after EBs were stained by immunocytochemistry.
3.3. Combining PKG and PKC Isotype-Speciﬁc Inhibitors Pro-
m o t e sE SC e l l - D e r i v e dC a r d i o m y o c y t eD i ﬀerentiation. When
ES cells are coaxed down the cardiomyocyte pathway, usually
a small percentage of ES cells become cardiomyocytes [5, 6,
17–19]. We previously showed that molecular manipulation
of the PKC pathway increased that percentage signiﬁcantly
[6] similar to manipulating the PKG pathway (above). Based
on these observations, we surmised that if both pathways
were inhibited signiﬁcantly more cardiomyocytes would
result when compared to manipulation of either pathway
alone or controls.
Analyzing over 100 EBs for each treatment, we rou-
tinely observed signiﬁcantly more EBs beating sooner after
incubation in DT-3 or DT-3 + either PKC inhibitor when
compared to control (Figure 3(a)). On average, by day 12
of diﬀerentiation, 10% untreated/DMSO control EBs had
beating areas, while ∼40% treated EBs contained beating
areas. This trend continued throughout the duration of the
experiment.
The combinatorial eﬀect of inhibiting PKG and PKC on
cardiomyocyte diﬀerentiation became clear when individual
beating areas were counted and averaged (Figure 3(b)). By
day 12, EBs treated only with DT-3 had a 20% diﬀerence
in beating areas versus controls, whereas by day 16 there
was a 40% diﬀerence between DT-3-inhibited EBs versus
controls. EBs treated with both DT-3 and PKC inhibitor had
a substantial percentage that peaked at an average of 55% on
day 15.
Beating patterns unique to PKG- and PKCβ-inhibited
EBs were also observed. After 14 days in culture, beat-
ing areas within PKG- and PKCβ−inhibited EBs covered
approximately 2X the total area of control EBs (Figure 3(c));
however, overall EB sizes were not aﬀectedbyinhibitoreither
alone or in combination. They also only exhibited minor cell
death around the edges (analyzed by trypan blue, data not
shown). Interestingly, contraction seemed to “ﬂow” between
two large, concurrent beating areas in PKG/PKC-inhibited
EBs, whereas beating areas in control EBs were normally
isolated.
Beating frequency was also measured; however, no
signiﬁcant diﬀerence was observed with respect to cardiomy-
ocytes diﬀerentiated with or without PKC/PKG inhibitors.
Control EBs beat rate was 78 + 5 beats/min, while beating
frequency for EBs treated with PKCβ,P K G ,a n dP K C β/PKG
inhibitors was 70 ± 6beats/min, 68 ± 5beats/min, and 65 ±
5beats/min, respectively.
3.4. Fluorescence-Activated Cell Sorting Reveals a Shift in EB-
Derived Cardiomyocyte Diﬀerentiation. Beating areas were
clearly larger in treated EBs; however, it was diﬃcult to
discern whether more cells were beating or, alternatively, the
samenumber ofbeating cellsasfoundin controlswassimply
dispersedoveralargerportionoftheEB.Todeterminewhich
scenario was correct, we subjected treated and untreated
EBs to FACS, which revealed that the type of treatment
aﬀected the production of ES cell-derived cardiomyocytes.
Although all treatments markedly increased the number of
cardiomyocytes when compared to control EBs, the highest
percentage of cardiomyocytes was found in EBs treated with
DT-3 + PKCβ inhibitor (Figure 4). These results conﬁrm
that manipulation of distinct signal transduction pathways
within EBs can coax more cells to become cardiomyocytes
than untreated control EBs.
3.5. qRT-PCR Suggests That PKG Act at the Gene Level of
CardiomyocyteDiﬀerentiation. Inthefollowingexperiments,
we compared untreated EBs with EBs treated with DT-
3 alone or DT-3 + PKCβ at day 12 post LIF removal.
We chose this time point based on our observations in
Figure 3, which showed that cardiomyocytes were observed
signiﬁcantly sooner in DT-3 or DT-3 + PKCβ inhibitor-
treated EBs when compared to untreated EBs.
When compared to untreated EBs at the same day,
at least 8 cardiac genes were upregulated in EBs treated
with DT-3 + PKCβ inhibitors (Figure 5(a)). Interestingly,
speciﬁc cardiac genes were enhanced when DT-3 + PKCβ
inhibitors were combined (Figure 5(b)). In DT-3-treated
EBs, ANP was increased 2.87-fold (Figure 5(a)), while ANP
was increased 6.37-fold in DT-3 + PKCβ inhibitor-treated
cells(Figure 5(b)).MLC2awasincreased95.24-foldinDT-3-
treated cells (Figure 5(a)); however, it was increased 251.29-
fold in DT-3 + PKCβ inhibitor-treated cells (Figure 5(b)).
DT-3 + PKCβ inhibitor-treated cells also had higher6 Stem Cells International
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Figure 3: Two days after plating each EB into a well of a 24-well plate (nine days after removal of LIF), DT-3 and DT-3 + PKCβ inhibitor,
or DT-3 + PKCζ inhibitor were added to diﬀerent EBs. Carrier alone and untreated EBs were used as controls. EBs were then analyzed for
beating two days later (Day 11 post LIF removal). As an added control, all four authors routinely performed blind counts of EBs to decrease
subjectiveness. Discrepancies between authors were rare, but when they occurred, the morphology observed by the majority of authors was
used as the data point. (a) Inhibiting PKG alone or in combination with PKCbeta or zeta resulted in signiﬁcantly more EBs with at least one
beating area when compared to controls. Signiﬁcance is shown in Table 1 at each time point. The combination of DT-3 + PKCbeta or zeta
inhibitors revealed in a trend towards more EBs that had at least one beating area when compared to DT-3 alone. Signiﬁcance (P<. 05) was
attained on Day 14. (b) Inhibiting PKG alone or in combination with PKCbeta or zeta resulted in signiﬁcantly more beating areas within EBs
when compared to controls. Signiﬁcance is shown in Table 2 at each time point. (c) A typical Day 14 EB outgrowth that has been subjected
to DT-3 and PKCbeta speciﬁc inhibitor. NB = nonbeating area, B = beating area. Arrows depict the directional ﬂow of contraction of the
larger beating area. Scale bar = 100 μmeter. The number of EBs analyzed for both (a) and (b) is depicted below their speciﬁc treatment (e.g.,
n = 211 EBs for DT-3 treatment).
Table 2: Signiﬁcance comparing treated groups to controls (for data points in Figure 3(b)) number beating areas. NS: no signiﬁcance.
DT-3 compared to controls
Day 12: NS Day 13: NS Day 14: NS Day 15: NS Day 16: P<. 006 Day 17: P<. 001
DT-3 + PKCζ inhibitor compared to controls
Day 12: NS Day 13: P<. 0001 Day 14: P<. 0001 Day 15: P<. 0006 Day 16: P<. 006 Day 17: P<. 02
DT-3 + PKCβ inhibitor compared to controls
Day 12: NS Day 13: NS Day 14: P<. 02 Day 15: P<. 02 Day 16: P<. 001 Day 17: P<. 02
expression of the cardiac-speciﬁc cytoskeleton marker, cTnT
(37.50-fold), when compared to DT-3-treated cells (3.85-
fold).
Interestingly, when comparing EBs treated with DT-3
alone versus DT-3 + PKCβ inhibitors at day 12 post LIF
removal, we found that atrial markers were upregulated
in DT-3 + PKCβ inhibitor-treated EBs. When all data are
combined, they support our hypothesis that simultaneous
inhibition of PKC and PKG increases the number of
cardiomyocytes when compared to untreated EBs, and in
addition,downregulationofPKCβ andPKGappearstoguide
them down the atrial pathway.Stem Cells International 7
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alone (blue line) markedly pushed more cells towards the cardiomyocyte lineage when compared to control EBs diﬀerentiated down the
cardiomyocte pathway (red line). (b)-(c) However, combining PKG and PKC inhibitors skewed ES cell diﬀerentiation further towards the
cardiomyocyte lineage when compared to DT-3-treated EBs (a) and control EBs with the highest number of cardiac troponin-positive cells
foundinEBstreatedwithDT-3andPKCbetaspeciﬁcinhibitor(b).(d)-(e)PKCinhibitorsalonealsoincreasedthenumberofcardiomyocytes
generated from ES cells but not to the extent of dual inhibition of PKCbeta and PKG. (f) Proportions of cardiac troponin expressing cells
from four experiments were analyzed using the two-sample test for binomial proportions. The proportion of CCE cells expressing cardiac
troponinwassigniﬁcantlyhighestinPKG/PKCbeta-(purplebar)inhibitedcellswhencomparedtoEBsdiﬀerentiatedwithoutdrugs(redbar;
P<. 001). Inhibiting both PKCβ and PKG resulted in the most signiﬁcant increase in cardiomyocytes when compared to all other treatments
(P values are shown for each comparison). Two types of controls were used for FACS analyses: (1) FACS machine parameters were set
by analyzing cells from diﬀerentiated EBs not subjected to any antibodies and cells from diﬀerentiated EBs subjected to only secondary
antibodies, and (2) cells from treated EBs were compared to cells from untreated (or DMSO carrier) EBs subjected to primary (anticardiac
troponin) and secondary antibodies. EBs diﬀerentiated without drugs (i.e., untreated) or without drugs but in DMSO carrier demonstrated
virtually identical proportions of diﬀerentiated cardiomyocytes (data not shown).8 Stem Cells International
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Figure 5: PKG in combination with PKC increases cardiac markers as shown by qRT-PCR. The time points in (a)–(c) are equivalent to
Day 12 in Figures 3(a) and 3(b). (a) Negative control (untreated) versus PKG inhibitor: treatment of EBs with DT-3 resulted in increased
early cardiac markers, atrial cardiac markers, the cardiac marker, Nkx2.5, as well as cardiac-speciﬁc cytoskeleton proteins when compared
to negative control (untreated) EBs. (b) negative control versus combined treatment of PKCβ inhibitor and DT-3: The combined treatment
of PKCβ and PKG inhibitors signiﬁcantly upregulated atrial cardiac markers and the cardiac troponin T gene. (c) DT-3 Treatment versus
combined treatment of PKCβ inhibitor and DT-3: the combined treatment of PKC and PKG signiﬁcantly upregulated both atrial markers,
ANP, and MLC2a, when compared to treatment with PKG alone. (d) Table describing cardiac markers used for qRT-PCR. Graph color code
= bars in graphs.
4. Discussion
Signal transduction mechanisms involving PKG1 have been
studied in many systems; however, the role of PKG1 in initial
cardiomyocyte diﬀerentiation is not well understood [20,
21]. A previous study showed that PKG1 protein and gene
expression are reduced in beating cardiomyocytes [22]. Here
weshowthatphysicallydownregulatingPKGinEScellsdur-
ing cardiomyogenesis generates more cardiomyocytes than
untreated controls. These results support our hypotheses
that downregulating PKG1 stimulates ES cell diﬀerentiation
into cardiomyocytes and that combining PKG/PKC speciﬁc
inhibitors results in signiﬁcantly more cardiomyocytes when
compared to either inhibitor alone or untreated controls.
Why would PKG and PKCβ and ζ need to be down-
regulated in beating areas? One answer is that PKG can
be activated by nitric oxide (NO) through activation of
guanylatecyclase,whichconvertsGTPintocGMP[7–9].NO
is continually present in ES cells especially during stages of
diﬀerentiation prior to the cardiac lineage [22, 23]. With theStem Cells International 9
evidence from past investigations demonstrating that cGMP
attenuates muscle contraction in adult cardiomyocytes [11,
24] by inhibiting the cardiac L-type CA2+ channel current
(ICa,L) and, along with PKA, the voltage-dependent fast Na+
current in ventricular myocytes [11], we conclude that ES
cells must downregulate PKG to enable activation of the car-
diomyocyteelectricalsystem.Also,inothersystems,PKGcan
phosphorylate MLC phosphatase resulting in inhibition of
contraction [10, 24], which could further impair contraction
in ES cell-derived cardiomyocytes if it is not downregulated.
The purpose for downregulating PKC has been described in
[6].
However, another answer is that PKG and PKC could
have been recruiting more ES cells to diﬀerentiate into car-
diomyocytes. DT-3 has been shown to only aﬀect the activity
of PKG and not to aﬀect gene transcription [25–28]. As a
result we propose that the upregulation of speciﬁc cardiac
g e n e si sd u et oar e l e a s eo fap u t a t i v eP K G / P K C β repression
mechanism. Once PKG and/or PKCβ are downregulated,
more cells within an EB can be recruited to enter the cardiac
pathway as PKG and PKC cardiac repressors involved in
transcription can become deactivated. PKG has been shown
to regulate gene expression under certain circumstances [29]
as has PKC [30].
Substantial research promise includes applying these
signal transduction ﬁndings to human adult stem cells
derived from cord blood, bone marrow, or the new iPS.
Though it is currently believed that adult stem cells are not
as ﬂexible as ES cells, it might be possible to apply these
methods to transdiﬀerentiate signiﬁcantly more adult stem
cellsintoembryonic-likecardiomyocytesfortherapeuticuse.
We are currently investigating the possibility of applying
these same PKG and PKC inhibitors to mesenchymal stem
cells. The results of this study could contribute to the
eﬀorts aimed at the ultimate goal of circumventing the
harmful aﬀects of natural cardiac remodeling and thus safely
rebuilding hearts damaged by heart attack or congestive
heart failure.
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